Clinical trials: BCC
Head and Neck Cancer, Oral Complications
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00017511
- Testing
- cevimeline hydrochloride
- Where
- 71 sites in United States
- Sponsor
- Daiichi Sankyo
Basal Cell Carcinoma, Skin Cancer
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when…
- Conditions
- Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin
- Trial name
- NCT05188729
- Testing
- Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose
- Where
- 13 sites in United States
- Volunteers
- 92 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Basal Cell Carcinoma
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
The primary objective of this study is to assess whether basal cell carcinoma (BCC) lesions surgically treated with curettage, followed by imiquimod 5% cream as postsurgical adjuvant therapy, will have an improved cure rate over…
- Trial name
- NCT00129519
- Testing
- Imiquimod 5% cream
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Nodular Basal Cell Carcinoma
Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
The primary objective is the observation and description of the preliminary efficacy of resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of patients.
- Trial name
- NCT01808950
- Testing
- 0.06% Resiquimod Gel - A, 0.06% Resiquimod Gel - B, 0.06% Resiquimod Gel - C
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 4 people
- Sponsor
- Spirig Pharma Ltd.
BCC
Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study
This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC.
- Trial name
- NCT02007317
- Testing
- Oshadi D & Oshadi R
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Oshadi Drug Administration
Basal Cell Carcinoma
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of superficial basal cell carcinoma.
- Trial name
- NCT00108134
- Testing
- PEP005
- Where
- 9 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin
Basal Cell Carcinoma
Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)
This is a multicenter, phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability, pharmacodynamics and preliminary efficacy of intra-lesional BO-112 in patients with resectable primary low and high…
- Trial name
- SPOTLIGHT204 (NCT06422936)
- Testing
- BO-112
- Where
- 10 sites in Israel, Spain
- Volunteers
- 50 people
- Sponsor
- Highlight Therapeutics
Skin Cancer
Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope
The primary objective is to collect emission spectra of normal tissue, pigmented normal lesion, benign lesion, SCC, BCC and melanoma to construct the database and validate the classifying algorithm.
- Trial name
- NCT03069846
- Testing
- Spectra-Scope
- Where
- Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sung Hyun Pyun
Basal Cell Carcinoma (BCC)
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
The aim of this study is to test the effectiveness and safety of the medicine Ameluz® (5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic therapy (PDT), to treat thin, non-aggressive BCC…
- Trial name
- NCT02144077
- Testing
- BF-200 ALA, methyl-aminolevulinate
- Where
- Germany
- Volunteers
- 281 people
- Sponsor
- Biofrontera Bioscience GmbH
Skin Neoplasms
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed.
- Trial name
- NCT02097875
- Testing
- BLZ-100
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Blaze Bioscience Australia Pty Ltd
Basal Cell Carcinoma
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.
- Trial name
- BOLT (NCT01327053)
- Testing
- LDE225
- Where
- 62 sites in United States, Australia and 10 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Basal Cell Carcinoma
Topical Vitamin C for Treatment of Basal Cell Cancer
Randomized coomparative trial of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice a day for 8 weeks vs 5% imiquimod cream in the treatment biopsy proven basal cell carcinomas inotherwise healthy…
- Trial name
- NCT04279535
- Testing
- Topical Ascorbic Acid
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Center for Biomedical Research, Inc.
Field Actinic Keratoses, Basal Cell Carcinoma
Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease
The aim of this study is to provide this investigational drug to patients who cannot be optimally treated with conventional therapies and to collect efficacy and safety data on the use of Metvix PDT in subjects with field actinic…
- Conditions
- Field Actinic Keratoses, Basal Cell Carcinoma, Bowen's Disease
- Trial name
- NCT00535080
- Testing
- Metvix (methyl aminolevulinate)
- Sponsor
- Galderma R&D
Skin Cancer, Cutaneous Tumor
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors
- Conditions
- Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis
- Trial name
- NCT04068155
- Testing
- DaRT- Diffusing Alpha-emitters Radiation Therapy
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Alpha Tau Medical LTD.
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma.
- Trial name
- NCT05157763
- Testing
- EscharEx 5% (EX-02 formulation)
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediWound Ltd
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Locally Advanced Basal Cell Carcinoma
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC.
- Trial name
- NCT07808515
- Testing
- Cemiplimab, Vidutolimod, Fianlimab
- Volunteers
- 135 people
- Sponsor
- Regeneron Pharmaceuticals
Basal Cell Carcinoma
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of nodular basal cell carcinoma.
- Trial name
- NCT00108121
- Testing
- PEP005
- Where
- 10 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin
Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the…
- Trial name
- NCT00604890
- Testing
- API 31510 3% Topical Cream, API 31510 1.5% Topical Cream
- Where
- 11 sites in United States
- Volunteers
- 186 people
- Sponsor
- BPGbio
Basal Cell Carcinoma
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
This multi-center, prospective, observational cohort study will evaluate the effectiveness, safety and utilization of treatments in patients with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome.
- Trial name
- NCT01604252
- Where
- 81 sites in United States, Puerto Rico
- Volunteers
- 503 people
- Sponsor
- Genentech, Inc.